Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Retapamulin

FDA-approved product (ointment, topical), marketed as Altabax.

Registered studies
19
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Retapamulin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Impetigo
  • Staphylococcal skin infections

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antibiotics for topical use
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC D06AX13

Repurposing investigation

Retapamulin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA63.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli47.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae39.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis43.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

19registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Retapamulin in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Retapamulin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus

    NCT00539994 · start 2007-09

    Registered record
    Registry ID
    NCT00539994
    Conditions
    Infections, Bacterial
    Interventions
    retapamulin; Retapamulin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-09
    Completion
    2008-01
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections, Bacterial
    Interventionretapamulin; Retapamulin; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Pharmacokinetics of Retapamulin in Pediatric Subjects With Uncomplicated Skin Infections.

    NCT00555061 · start 2007-09

    Registered record
    Registry ID
    NCT00555061
    Conditions
    Skin Infections, Bacterial
    Interventions
    Retapamulin Ointment, 1%
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-09
    Completion
    2008-08
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Infections, Bacterial
    InterventionRetapamulin Ointment, 1%
    PhasePhase 4
    Registry statusCompleted

  • Treatment Of Impetigo With Topical SB-275833 Ointment, 1% Versus Topical Placebo Ointment

    NCT00133848 · start 2005-04

    Registered record
    Registry ID
    NCT00133848
    Conditions
    Impetigo
    Interventions
    SB-275833 ointment, 1%
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-04
    Completion
    2006-01
    Enrolment
    210

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionImpetigo
    InterventionSB-275833 ointment, 1%
    PhasePhase 3
    Registry statusCompleted

  • Topical SB-275833 Ointment, 1% For The Treatment Of Impetigo

    NCT00133874 · start 2005-04

    Registered record
    Registry ID
    NCT00133874
    Conditions
    Skin Infections, Bacterial
    Interventions
    SB-275833 ointment, 1%
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-04
    Completion
    2005-09
    Enrolment
    520

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSkin Infections, Bacterial
    InterventionSB-275833 ointment, 1%
    PhasePhase 3
    Registry statusCompleted